Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Instituto Grifols, S.A. Clear all
Terminated Phase 2Phase 3 Interventional Results available

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

NCT02176863
View directory record Official record
Conditions
Post-polio Syndrome
Interventions
Flebogamma® 5% DIF, Placebo
Biological · Drug
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

NCT07264517
View directory record Official record
Conditions
Dry Eye Disease
Interventions
GRF312 5%, Placebo Comparator
Drug · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Glendale, California • Grove, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

NCT02281500
View directory record Official record
Conditions
Congenital Afibrinogenemia
Interventions
Human Plasma-Derived Fibrinogen Concentrate
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
Up to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

NCT03461406
View directory record Official record
Conditions
Excessive Bleeding During Surgery
Interventions
Fibrin Sealant Grifols, EVICEL
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Up to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chicago, Illinois • Michigan Center, Michigan • Albany, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

NCT01731938
View directory record Official record
Conditions
Soft Tissue Surgical Bleeding
Interventions
Fibrin Sealant (FS) Grifols, Surgicel®
Biological · Device
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
Not listed
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Florence, Alabama • Pasadena, California • Bridgeport, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

NCT00742417
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albutein 5%, Control
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Whiting, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

NCT01754480
View directory record Official record
Conditions
Parenchymous Tissue Surgical Bleeding
Interventions
Fibrin Sealant Grifols, Surgicel®
Biological · Device
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 7, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

NCT03702920
View directory record Official record
Conditions
Acute-On-Chronic Liver Failure
Interventions
SMT + PE-A 5%, Standard Medical Treatment
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

NCT03585257
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions
25% IV albumin, Placebo
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

NCT01662856
View directory record Official record
Conditions
Vascular Surgical Bleeding
Interventions
Fibrin Sealant Grifols, Manual Compression
Biological · Procedure
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Florence, Alabama • Palo Alto, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569
View directory record Official record
Conditions
Primary Immune Deficiency Disease
Interventions
Flebogamma 5% DIF
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
St. Petersburg, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

NCT03451292
View directory record Official record
Conditions
Decompensated Cirrhosis and Ascites
Interventions
Albutein 20%, SMT
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Coronado, California • Miami, Florida • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

IGIV Study for Chronic ITP Patients Ages 3-70

NCT00511147
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
IGIV3I Grifols 10%
Biological
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
3 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 7, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

NCT02014402
View directory record Official record
Conditions
Hemostasis
Interventions
Human thrombin, Bovine thrombin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 7, 2026, 5:22 AM EDT